Next Article in Journal
Differential Expression of CD3, TNF-α, and VEGF Induced by Olanzapine on the Spleen of Adult Male Albino Rats and the Possible Protective Role of Vitamin C
Previous Article in Journal
Evaluation of Angiogenesis Assays
Previous Article in Special Issue
The TLR3 Agonist Poly Inosinic:Cytidylic Acid Significantly Augments the Therapeutic Activity of an Anti-CD7 Immunotoxin for Human T-Cell Leukaemia
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview

Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression

1
Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milan, Italy
2
MIUR, Italian Ministry of Instruction, University and Research, 20090 Monza, Italy
3
Università Vita-Salute San Raffaele, 23132 Milan, Italy
*
Author to whom correspondence should be addressed.
Biomedicines 2019, 7(2), 38; https://doi.org/10.3390/biomedicines7020038
Received: 31 March 2019 / Revised: 7 May 2019 / Accepted: 13 May 2019 / Published: 17 May 2019
(This article belongs to the Special Issue Immunotoxins: Future Advances and Directions)
  |  
PDF [805 KB, uploaded 17 May 2019]
  |  

Abstract

For the recombinant expression of toxin-based drugs, a crucial step lies not only in the choice of the production host(s) but also in the accurate design of the protein chimera. These issues are particularly important since such products may be toxic to the expressing host itself. To avoid or limit the toxicity to productive cells while obtaining a consistent yield in chimeric protein, several systems from bacterial to mammalian host cells have been employed. In this review, we will discuss the development of immunotoxin (IT) expression, placing special emphasis on advantages and on potential drawbacks, as one single perfect host for every chimeric protein toxin or ligand does not exist. View Full-Text
Keywords: recombinant immunotoxin; bacterial/eukaryotic expression systems; ribosome inactivating proteins; toxin-based drugs recombinant immunotoxin; bacterial/eukaryotic expression systems; ribosome inactivating proteins; toxin-based drugs
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Zuppone, S.; Fabbrini, M.S.; Vago, R. Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression. Biomedicines 2019, 7, 38.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top